Brief: Cullinan Oncology Announces First Patient Dosed In Phase 1 Trial Evaluating Cln-617, A Novel Fusion Protein Uniquely Harnessing Both Il-2 And Il-12 Cytokines

Cullinan Therapeutics

14/12/2023 22:40

Dec 14 (Reuters) - Cullinan Oncology Inc  CGEM.O :
    * CULLINAN ONCOLOGY ANNOUNCES FIRST PATIENT DOSED IN PHASE 1
TRIAL
EVALUATING CLN-617, A NOVEL FUSION PROTEIN UNIQUELY HARNESSING
BOTH IL-2 AND IL-12 CYTOKINES

Source text for Eikon:  ID:nGNX7K4KnG 
Further company coverage:  CGEM.O 

 ((Reuters.Briefs@thomsonreuters.com;))